Cellares will collaborate with the Stanford Center for Definitive and Curative Medicine (CDCM) and Stanford Innovative Medicines Accelerator (IMA) to automate manufacturing and release testing for gene-edited hematopoietic stem cell (HSC) therapies, expanding the application of Cellares’ automation platforms beyond T cell therapies.

Gene-edited HSCs are being developed as potentially one-time treatments that rebuild the blood and immune system with corrected cells for patients with HIV and rare inherited diseases. Many of these conditions currently lack effective treatment options, highlighting the need for scalable, reliable manufacturing approaches that can support patient access as programs advance.

Cellares will establish a standardized platform manufacturing process on the Cell Shuttle™ and platform release assays on the Cell Q™, designed to apply across multiple indications. Automation efforts are already underway with the Harbor Knock (safe harbor knock-in) gene-editing approach. The collaboration aims to reduce hands-on variability and create a scalable foundation to help move academic innovation toward clinical development.

Matthew Porteus, MD, PhD, director of the CDCM at Stanford University School of Medicine, and his lab have developed an HSC gene-editing approach that can be applied across HIV and a wide range of monogenic diseases, according to Fabian Gerlinghaus, co-founder and CEO of Cellares. One of their goals is to identify a manufacturing process that is consistent and scalable.

“Gene-edited hematopoietic stem cells have the potential to address the root cause of disease for patients who today have limited or no treatment options,” says Gerlinghaus. “With Stanford Medicine, we’re building a manufacturing and analytical foundation that can be applied across many rare disease programs to improve patient access.”